65 related articles for article (PubMed ID: 21178358)
21. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus.
Tsuge M; Hiraga N; Takaishi H; Noguchi C; Oga H; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Chayama K; Tateno C; Yoshizato K
Hepatology; 2005 Nov; 42(5):1046-54. PubMed ID: 16250045
[TBL] [Abstract][Full Text] [Related]
22. Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient mice.
Kawahara T; Douglas DN; Lewis J; Lund G; Addison W; Tyrrell DL; Churchill TA; Kneteman NM
Transpl Int; 2010 Sep; 23(9):934-43. PubMed ID: 20180929
[TBL] [Abstract][Full Text] [Related]
23. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone.
Maeda N; Watanabe M; Okamoto S; Kanai T; Yamada T; Hata J; Hozumi N; Katsume A; Nuriya H; Sandhu J; Ishii H; Kohara M; Hibi T
Liver Int; 2004 Jun; 24(3):259-67. PubMed ID: 15189278
[TBL] [Abstract][Full Text] [Related]
25. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
[TBL] [Abstract][Full Text] [Related]
26. The SCID-hu mouse as a model for HIV-1 infection.
Aldrovandi GM; Feuer G; Gao L; Jamieson B; Kristeva M; Chen IS; Zack JA
Nature; 1993 Jun; 363(6431):732-6. PubMed ID: 8515816
[TBL] [Abstract][Full Text] [Related]
27. Development of functional human immune system with the transplantations of human fetal liver/thymus tissues and expanded hematopoietic stem cells in RAG2-/-gamma(c)-/- MICE.
Joo SY; Choi BK; Kang MJ; Jung DY; Park KS; Park JB; Choi GS; Joh J; Kwon CH; Jung GO; Lee SK; Kim SJ
Transplant Proc; 2009 Jun; 41(5):1885-90. PubMed ID: 19545750
[TBL] [Abstract][Full Text] [Related]
28. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo.
Bukowski JF; Woda BA; Habu S; Okumura K; Welsh RM
J Immunol; 1983 Sep; 131(3):1531-8. PubMed ID: 6309965
[TBL] [Abstract][Full Text] [Related]
30. Engraftment of human synovium into severe combined immune deficient mice. Migration of human peripheral blood T cells to engrafted human synovium and to mouse lymph nodes.
Rendt KE; Barry TS; Jones DM; Richter CB; McCachren SS; Haynes BF
J Immunol; 1993 Dec; 151(12):7324-36. PubMed ID: 8258726
[TBL] [Abstract][Full Text] [Related]
31. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
32. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Petersen J; Dandri M; Mier W; Lütgehetmann M; Volz T; von Weizsäcker F; Haberkorn U; Fischer L; Pollok JM; Erbes B; Seitz S; Urban S
Nat Biotechnol; 2008 Mar; 26(3):335-41. PubMed ID: 18297057
[TBL] [Abstract][Full Text] [Related]
33. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
Devalapally H; Shenoy D; Little S; Langer R; Amiji M
Cancer Chemother Pharmacol; 2007 Mar; 59(4):477-84. PubMed ID: 16862429
[TBL] [Abstract][Full Text] [Related]
34. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
35. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
[TBL] [Abstract][Full Text] [Related]
36. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
37. Novel HCV replication mouse model using human hepatocellular carcinoma xenografts.
Guévin C; Lamarre A; Labonté P
Antiviral Res; 2009 Oct; 84(1):14-22. PubMed ID: 19622372
[TBL] [Abstract][Full Text] [Related]
38. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.
Huang LR; Wu HL; Chen PJ; Chen DS
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17862-7. PubMed ID: 17095599
[TBL] [Abstract][Full Text] [Related]
39. [Establishment and application of engrafted tumor models with humanized tumor blood vessel].
Ran YL; Zhong X; Hu H; Yu L; Lou JN; Yang ZH
Ai Zheng; 2006 Nov; 25(11):1323-8. PubMed ID: 17094895
[TBL] [Abstract][Full Text] [Related]
40. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
De Ruysscher D; Sobis H; Vandeputte M; Waer M
J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
